Remove Pharmaceutical Remove Safety Remove Therapy
article thumbnail

A Glimpse Inside the Lichen Planus Pipeline

The Dermatology Digest

Several new therapies are coming down the pike for the treatment of lichen planus, a chronic inflammatory condition that affects an estimated 1% to 2% of the global population, according to a new report from Research and Markets. Incyte is investigating the efficacy and safety of ruxolitinib cream in cutaneous lichen planus.

article thumbnail

Tildrakizumab (Ilumya, Sun Pharma) Improves Moderate-to-severe Nail PsO

The Dermatology Digest

Tildrakizumab-asmn (Ilumya, Sun Pharmaceutical Industries, Inc.) ” The safety profile was consistent with the known safety profile of tildrakizumab, and no serious adverse events related to ILUMYA treatment occurred in this clinical trial,the study showed. .

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy.

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. alone and no FDA approved therapies, common warts represent one of the largest unmet needs in all of dermatology. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

Biosimilar News: Stada, Alvotech Launch the First Ustekinumab Biosimilar Across Europe

The Dermatology Digest

Launching Uzpruvo at the earliest opportunity in Europe’s largest pharmaceutical markets, promotes access by creating competition,” says STADA CEO Peter Goldschmidt in a news release. Launches in further European countries are scheduled over the coming months, following national price approvals, via a fully European supply chain.

article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor-blinded, head-to-head, multi-center study evaluating upadacitinib vs. dupilumab in adolescents and adults with moderate-to-severe AD who had an inadequate response to systemic therapy or when the use of those therapies was inadvisable.

article thumbnail

What does Mandelic Acid do in Deodorants – The Beauty Brains solo

The Beauty Brains

So, pharmaceutical companies are spending money researching this. J&J might discover something as they are a pharmaceutical company, but most beauty companies are not set up to develop these types of products. I’ll say up front, there is little evidence that cupping therapy has any real benefits. I feel your pain.